Gan & Lee Pharmaceuticals' third-quarter results miss expectations: Overseas licensing revenue delayed, while innovative drug progress supports growth outlook
Third-quarter revenue rose 16.9% year on year, but Goldman Sachs said a delay in recognizing business development and licensing revenue weighed on results. Overseas sales and two innovative drug candidates made progress, while potentially higher R&D spending prompted Goldman Sachs to lower its earnings forecasts for the next two years.
Goldman Sachs ·